Search PubMed⌕ Search

Biomedical subjects

U Berger

Publications and source records attributed to U Berger.

At least 127 records · Page 7Linked to original sources
PubMed1986

Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy.

We developed an immunoperoxidase technique using a monoclonal antibody to the estradiol receptor (ER) to identify immunoreactive ER (iER) in breast carcinomas and compared this with the conventional dextran-coated charcoal (DCC) steroid binding assay. We also examined the relationship between the iER and response to therapy in patients with advanced breast cancer. We found iER-positive cells in 60 of 90 carcinomas (66.7%); this correlated with the DCC assay (r = 0.76; P less than .001). Of these, 56 patients were found to be assessable for response to endocrine therapy. Twenty-two showed an objective response to some form of endocrine manipulation, and all these had positively stained carcinomas. By deriving a staining intensity index (SII) we observed that 21 of 22 responders (95%) had an SII of greater than or equal to 0.5, whereas only 8 of 34 nonresponders (24%) had an SII of greater than or equal to 0.5. This difference is highly significant (P less than .001). None of the 17 patients with negatively stained carcinomas responded to endocrine therapy. We conclude that the monoclonal antibody to ER can help identify breast cancer patients who may respond to endocrine therapy.

Aminoglutethimide↗
PubMed1986

Immunocytochemical assay for estrogen receptor: relationship to outcome of therapy in patients with advanced breast cancer.

We have used an immunoperoxidase technique utilizing a monoclonal antibody to the estradiol receptor to identify immunoreactive estradiol receptor in breast carcinomas and have examined the relationship between the immunoreactive estradiol receptor and response to therapy in patients with advanced breast cancer. Fifty-six patients were found to be assessable for response to endocrine therapy. Twenty-two showed an objective response to some form of endocrine manipulation, and all these had positively stained carcinomas. None of the 17 patients with negatively stained carcinomas responded to endocrine therapy. We conclude that the monoclonal antibody to estradiol receptor can help identify breast cancer patients who may respond to endocrine therapy.

Antibodies, Monoclonal↗
PubMed1986

Prognostic significance of micrometastases in bone marrow in patients with primary breast cancer.

Metastatic breast cancer cells were found in the bone marrow of 60 (23%) of 269 patients with primary breast cancer, none of whom had metastatic disease disclosed by any other investigation, including bone scanning and radiological skeletal survey. We estimated the number of cancer cells as less than or more than 20 cancer cells seen. Twenty-six patients had less than 20 cancer cells present, and 34 had 20 or more. At a median follow-up time of 22 months, 53 patients had relapsed, 19 of 60 (31.7%) in the group found to have micrometastases and 34 of 195 (17.2%) in the group that had normal bone marrow. Patients with micrometastases are relapsing at a faster rate than those without micrometastases (P = less than 0.05). Patients with less than 20 cancer cells present are relapsing faster than those with no cancer cells but slower than those with 20 or more cancer cells (P = less than 0.01). We conclude that the presence of cancer cells in the marrow at primary diagnosis is a prognostic factor in patients with primary breast cancer.

Bone Marrow Diseases↗
PubMed1985

Prevalence of Gemella haemolysans on the pharyngeal mucosa of man.

By culturing pharyngeal swabs from 199 students a carrier rate for Gemella haemolysans of 29.7% was detected. Demonstration of hemolysis depended on blood species and on agar base. Optimum growth was obtained under aerobic conditions in a 10% CO2-enriched atmosphere. The cells divided in two planes which were not regularly at right angles to each other. They appeared to be surrounded by a small capsule. Contrary to earlier descriptions, acid was produced from galactose, acetoin was produced by practically all strains and nitrite was reduced by all strains. Acid production from trehalose and N-acetyl-glucosamine, alkaline and acid phosphatase, C4 and C8 esterase, pyrrolidone arylamidase and phosphoamidase activities were detected. In tube precipitation, antigenic relations between type strain and the new isolates were demonstrated.

Adult↗
PubMed1984

Inhibition of Neisseria meningitidis by alpha-amylase.

alpha-Amylase inhibits growth not only of N. gonorrhoeae and Legionella pneumophila as obtained in literature (2), but also of N. meningitidis and certain isolates of different bacterial species. Therefore, tests for differentiation of gonococci from other species based upon sensitivity to alpha-amylase are of questionable value.

Drug Resistance, Microbial↗
PubMed1981

[Tetanus antibody screening in blood donors].

Two ELISA test methods for detection of tetanus antibodies are presented which are suitable for routine screening. Administration of the tests to blood donors shows good average immunization of the Swiss population against tetanus. Due to compulsory immunization during military service, men exhibit markedly higher antibody levels against tetanus than women. Some of the tested blood donors have rather high tetanus antibody titers, and it would be worth collecting plasma from these donors by plasmapheresis for production of a high-titred antitetanus hyperimmunoglobulin.

Adult↗
PubMed1981

[The identification of nonfermentative gram-negative bacteria. Experiences with 676 apyocyaninogenic strains (author's transl)].

During a period of 16 months 1757 strains of nonfermentative gram-negative rods have been isolated from clinical material. Of the, 1205 (69%) were P. aeruginosa, 124 (10%) of which failed to produce pyocyanin. The apyocyaninogenic strains as well as the remaining 552 isolates were differentiated by steps according to a diagnostic scheme developed by us. For identification of species two or three steps were needed. By this procedure, 530 of the 552 strains could be assigned to nineteen species within the genera Pseudomonas, Achromobacter, Alcaligenes, Flavobacterium, Agrobacterium and Acinetobacter. 17 strains could not be identified below the genus level, one strain belonged to CDC-group VE-2 and four strains were not identifiable. 72% of the 552 strains belonged to only four species: Pseudomonas putida, P. maltophilia, Acinetobacter lwoffii and A. anitratus.

Bacteria↗
PubMed1980

Griseorubins, a new family of antibiotics with antimicrobial and antitumor activity. I. Taxonomy of the producing strain, fermentation, isolation and chemical characterization.

A new antibiotic complex has been obtained from the cultures of Streptomyces strain No. IMET 20978 isolated from the shrimp Crangon crangon L. On the basis of taxonomic studies the producing microorganism is described as Streptomyces fimicarius (Duché) Waksman et Henrici, 1948, type strain IMET 20978. The antibiotic complex, designated as griseorubin, belongs to the polycyclic C-glycosyl antibiotics. It is a red-coloured amorphous material which consists of eight closely related fractions including griseorubins A, B, C, D, E, F, G, and H. The griseorubin complex exhibits antibiotic activity against Gram-positive and -negative bacteria as well as against mycoplasma and protozoa. The griseorubin complex is also effective on leukemia L1210 AND Zajdela ascites hepatoma.

Antibiotics, Antineoplastic↗
PubMed1980

Griseorubins, a new family of antibiotics with antimicrobial and antitumor activity. II. Biological properties and antitumor activity of the antibiotic complex griseorubin.

The antibiotic complex griseorubin has antimicrobial activity against Gram-positive as well as -negative bacteria, mycobacteria, mycoplasma and protozoa in vitro but it is not active against yeast and fungi. Tests with transplantable rodent tumors indicate that griseorubin is inhibitory to the growth of lymphatic leukemia L1210 in mice and Zajdela ascites hepatoma in rats. The acute LD50 of griseorubin in mice is 50 mg/kg of body weight when given intraperitoneally. Attempts to potentiate the antitumor activity by complexing with DNA proved to be unsuccessful.

Animals↗